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We report a 15-year-old girl with VAC14 gene-related juvenile parkinsonism-dystonia 
with substantial response to deep brain stimulation to the globus pallidus (GPi-DBS).  
The patient was born in a middle-eastern country from consanguineous parents. Her 
past medical and family histories were unremarkable. At 12 years of age she developed 
focal dystonia of her left hand, which generalized over 2-1/2 years (supplementary 
video 1). She developed bradykinesia and freezing of gait, with intact cognition. Medical 
treatment was ineffective.  
MRI of the brain demonstrated restricted diffusion of the bilateral corpus striatum, and 
T2 hypointensity with increased susceptibility of the globus pallidus and substantia nigra 
consistent with abnormal mineralization (figure 1) A clinically available gene panel 
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evaluating diseases in the spectrum of neurodegeneration with brain iron accumulation 
(NBIA) was non-diagnostic.  
A chromosomal microarray returned with a duplication at 16p13.11 and multiple areas 
of homozygosity comprising 3% of the genome. The duplication was thought to be an 
incidental finding, given mismatch between patient and typical phenotype. Upon 
reviewing the areas of homozygosity, the VAC14 gene stood out as potential candidate 
based on previous reports. 1–3 
 
Sequencing of the VAC14 gene identified a homozygous missense variant of unknown 
significance (p.Lys651Glu, c.1951A>G). The variant has not been previously described 
in publicly available databases (gnomAD, Exome Variant Server or 1000 Genomes), 
and involves a highly conserved amino acid in the protein C-terminal dimerization 
domain, where previous pathogenic mutations have been located. 1,4 The alteration is 
non-conservative from a positively charged amino acid to a negatively charged one. In 
silico analysis with Mutation Taster predicted it to be disease-causing, but Align GVGD 
and SIFT predicted the variant to be benign and tolerated.  
 
Patient’s skin fibroblasts were analyzed for abnormal endolysosomal morphology, 
associated with loss of VAC14 function.5–7 Patient cells as well as control human 
fibroblasts were cultured at equal density in full media for 24 hours. Fields of the cells 
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were imaged and scored for the presence of visible perinuclear vacuoles. Cell culture – 
experiments using primary fibroblasts were carried out.1 Briefly, all images were live 
cells captured using Leica DMIRB inverted fluorescence microscope. Transfections 
were carried out using Liofectamine 3000 (ThermoFisher).  
The patient’s fibroblasts demonstrated evidence of abnormal vacuolization in 76 ± 2% of 
cells. In a second experiment, normal VAC14 transfected into patient cells rescued the 
vacuoles, while GFP alone did not (supplementary figure 2). 
At 15 years old the patient underwent GPi-DBS, based on literature supporting benefit 
of pallidal stimulation in early-onset dystonia and brain iron accumulation syndromes. 8,9  
On initial examination, she had fluctuating tone without rigidity, 1+ hypomimia, 3+ 
symmetric bradykinesia and generalized dystonia. There was no resting, postural or 
kinetic tremor. She endorsed fatigue, constipation and joint pain. There was no 
cognitive change, dysautonomia or REM-sleep behavior disturbance. After 6 months of  
DBS, there was improvement in facial animation,  2+ bradykinesia and recovery of 
ambulatory capacity. She required 5 steps to recover from the pull test, with 
spontaneous retropulsion.  Freezing of gait was noted upon turns. Dystonia was much 
improved. Baseline Burke Fahn Marsden (BFM) motor score was 86.5/120, disability 
score was 27/30. Within 6 months, motor score improved by 76% (to 21) and disability 
score improved by 56% (to 12, supplementary video 2). The patient also endorsed 
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improvements in pain and fatigue, but these were not formally measured. Medications 
and programming settings can be seen in supplementary table 1.  
 
VAC14 encodes a dimeric scaffold protein that binds the lipid kinase PIKFYVE and the 
phosphatase FIG4. All three components are necessary for the synthesis of PI(3,5)P2 in 
the endolysosomal membrane compartment. The mechanism leading to enlarged 
endolysosomal vacuoles is not known precisely, but it is postulated that decreased 
levels of PI(3,5)P2 induce an osmotic effect. Alternatively, it is possible that dysfunction 
occurs through defects in membrane retrieval or fusion/fission.   
Biallelic mutations in the VAC14 gene have been associated with three allelic disorders: 
childhood striatonigral degeneration, juvenile parkinsonism-dystonia and Yunis-Varon-
like syndrome1 Precise genotype-phenotype correlation is lacking, although it appears 
that truncating variants are associated with more severe phenotypes. Mouse models 
present with neurodegeneration and enlarged endolysosomal vacuoles, recapitulating 
the neuropathologic findings from human subjects.6,7,10  In the few patients reported so 
far, age of onset seems to range from 1.5 to 13 years with onset of dystonia in a limb 
with rapid generalization affecting gait.1,3,10 Imaging may demonstrate  diffusion 
restriction in the striatum and susceptibility-weighed hypointensity in the pallidum and 
substantia nigra.1 (supplementary table 2). 
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We believe that VAC14-related parkinsonism dystonia should be considered in the 
differential diagnosis of NBIAs, especially if available genetic panels are negative. To 
our knowledge, there is no effective treatment. Our patient experienced substantial 
improvement in dystonia with GPi-DBS, but it is unclear whether benefit will be 
sustained. GPi-DBS may be considered if there is failure of medical therapy. 
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Figure legends: 
 
Figure 1. Axial SWI (A,B, E, F), FLAIR (C,G), and diffusion trace (D,H) sequences for 
the VAC14 proband at 14 years of age (A-D) and an age/sex matched control evaluated 
for headache (E-H). SWI imaging demonstrates abnormal susceptibility in the globus 
pallidus internus (arrows, A) and substantial nigra (arrows, B) as well as subtle diffusion 
abnormality in the corpus striatum (arrows, D). There was no convincing T2/FLAIR 
hyperintensity in the basal ganglia or substantia nigra (C).  
Figure 2. Vacuolization of patient fibroblasts is rescued with VAC14. A) Live cell image 
of representative perinuclear vacuolization (arrow) seen in patient skin fibroblasts. B) 
Patient fibroblast vacuolization rescued by cotransfection of VAC14 and GFP. C) 
Quantification of vacuolization in patient and control fibroblasts as well as rescue of 
vacuolization following VAC14 transfection. (Scale bars, 50 µm; Error bars, standard 
deviation)  
 
Video legends: 
Video 1: Baseline. The patient is non-ambulatory, with severe generalized dystonia 
affecting the neck, trunk and extremities. Bradykinesia is noted on repeated finger 
tapping. 
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Video 2: First segment: 3 months after DBS. There is improvement in truncal and 
appendicular dystonia. Segment 2:  6 months after DBS. Further improvement in 
dystonia is noted. The patient can walk independently. 
 
Supplementary material legends: 
 
Supplementary Table 1: Deep Brain Stimulation settings, Burke-Fahn Marsden scale 
and medications 
Supplementary Table 2: Published reports of VAC14-related gene disorders, at the 
time of manuscript submission. Table includes genetic and clinical characteristics. 
Papers are referenced in the bibliography section of the main manuscript.  
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http://www.wiley.com/go/funderstatement.  Additional terms may be applicable.  Please contact the 
production editor for the journal at MDCPprod@wiley.com if you have additional funding requirements. 
If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, 
the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository 
after the following applicable embargo period has expired, subject to further conditions imposed by the 
RCUK:  
a. 12 months from first publication online of the final published version of the Contribution for 
research funded by members of the Research Councils UK (RCUK) other than The 
Economic and Social Research Council (ESRC) and the Arts and Humanities Research 
Council (AHRC); or 
b. 24 months from first publication online of the final published version of the Contribution for 
research funded by ESRC or AHRC. 
5.  Additional Terms for Certain Institutions.  Wiley has arrangements with certain educational 
institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo 
period.    Details of such arrangements are set out at the following website: 
http://olabout.wiley.com/WileyCDA/Section/id-406074.html . Additional terms may be applicable. 
If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s 
OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in 
the educational institution’s repository after the following applicable embargo period has expired. See the 
following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.  
This article is protected by copyright. All rights reserved.
D. CONTRIBUTIONS OWNED BY EMPLOYER  
If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a 
“work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution 
which must execute this Agreement (in addition to the Contributor’s signature). In such case, the 
company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to 
the Contribution for the full term of copyright throughout the world as specified in Section A above.  
 E. GOVERNMENT CONTRACTS  
In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may 
reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official 
U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, 
U.K. Government, and other government employees: see notes at end.) 
F. CONTRIBUTOR’S REPRESENTATIONS  
The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified 
as Contributors actually contributed to the Contribution, and all individuals who contributed are included. 
The Contribution is submitted only to this Journal and has not been published before. (If excerpts from 
copyrighted works owned by third parties are included, the Contributor will obtain written permission from 
the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit 
to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous 
or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent 
or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or 
injury.  Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing 
the data on which the Contribution is based for examination by the editors or their assignees. 
G. FINANCIAL DISCLOSURES 
The Contributor certifies that his/her financial and material support for this research and work, regardless of 
date, is clearly identified on Exhibit A to this Agreement.  The Contributor has also identified on Exhibit A, 
all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, 
advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, 
or stock ownership in medically-related fields). 
H. VIDEO AND PHOTOGRAPHY CONSENT 
In the event that the Contribution includes, discloses or incorporates any content (including, without 
limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable 
content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or 
incorporation and that this consent fully complies with all legal requirements, including without limitation, 
all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician 
are subject, including the United States Health Insurance Portability and Accountability Act of 1996 
(“HIPAA”) if applicable.  The Contributor hereby certifies that, if the patient consent form is in a language 
other than English, such consent form meets all of the requirements set forth in the Instructions to Authors.  
In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the 
patient identifiable content in both print and online (i.e., internet/web-based) publication formats.  The 
Contributor further certifies that the person executing any such patient consent form, to the best of his/her 
knowledge, had legal capacity under applicable law to execute the form on behalf of the patient. 
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COPYRIGHT TRANSFER AGREEMENT 
Date: 
Contributor name:         
Contributor address:         
Manuscript number:         
Re: Manuscript entitled:           (the “Contribution”)  
for publication in:  Movement Disorders Clinical Practice (the “Journal”)  
Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the 
“Owner”) 
Dear Contributor(s):  
Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing 
process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this 
Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the 
Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed 
without a signed copy of this Agreement. 
 COPYRIGHT 
The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all 
copyright in and to the Contribution, and all rights therein, including but not limited to the right to 
reproduce, publish, republish, transmit, sell, transfer, distribute and otherwise use the Contribution in whole 
or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all 
languages and in all media of expression now known or later developed, and to license or permit others to do 
so.  
B. RETAINED RIGHTS  
Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all 
proprietary rights other than copyright, such as patent rights, in any process, procedure or article of 
manufacture described in the Contribution.   This reservation of rights does not affect or limit the rights 
assigned to Owner in Section A.  
C. PERMITTED USES BY CONTRIBUTOR  
1. License.  The Owner grants to Contributor a non-exclusive, non-transferable and limited license to 
reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the 
original form submitted to the Journal prior to the peer review process, solely to colleagues within the 
Contributor’s nonprofit organization or educational institution.  The Contributor shall make no more than 
100 printed copies of the preprints in any calendar year.   Such preprints may be posted as electronic files on 
the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit 
organization or educational institution, or on a secure external website at the Contributor’s nonprofit 
organization or educational institution, provided that access is limited to employees and/or students at 
Contributor’s non-profit organization or educational institution.    Contributor shall not charge a fee for any 
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preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any 
systematic external distribution (e.g., posting on a listserve, public website, database connected to a public 
access server, or automated delivery system).  The license grant in this Section does not apply to for-profit 
corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing 
by the Owner.  The rights granted to Contributor under this Section C do not include reproduction, 
distribution or any other use of rating scales, videos or other audiovisual materials associated with the 
Contribution. 
2. Required Citation.  Prior to publication, the Contributor must provide full credit and acknowledgement 
of the Journal in all preprints in the following format:  This is a preprint of an article accepted for 
publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder 
Society.   After publication, the Contributor must provide a citation to the Journal in all preprints in the 
following format:  This is a preprint of an article that was published in [Journal title]:  (Title of Article, 
Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and 
Movement Disorder Society).  An electronic link must be provided to the Journal’s website, located at 
http://www.interscience.Wiley.com.  The Contributor agrees not to update the preprint or replace it with the 
published version of the Contribution.    
3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version 
of the Contribution (the “Accepted Version”) is not permitted under this Agreement.  There are separate 
arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms 
apply if the Contributor receives or received funding from these agencies. The details of those relationships, 
and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/ 
funderstatement.  
4. Additional Terms for Certain Funders.  Certain funders, including the NIH, members of the Research 
Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository 
after an embargo period.   Details of funding arrangements are set out at the following website: 
http://www.wiley.com/go/funderstatement.  Additional terms may be applicable.  Please contact the 
production editor for the journal at MDCPprod@wiley.com if you have additional funding requirements. 
If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, 
the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository 
after the following applicable embargo period has expired, subject to further conditions imposed by the 
RCUK:  
a. 12 months from first publication online of the final published version of the Contribution for 
research funded by members of the Research Councils UK (RCUK) other than The 
Economic and Social Research Council (ESRC) and the Arts and Humanities Research 
Council (AHRC); or 
b. 24 months from first publication online of the final published version of the Contribution for 
research funded by ESRC or AHRC. 
5.  Additional Terms for Certain Institutions.  Wiley has arrangements with certain educational 
institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo 
period.    Details of such arrangements are set out at the following website: 
http://olabout.wiley.com/WileyCDA/Section/id-406074.html . Additional terms may be applicable. 
If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s 
OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in 
the educational institution’s repository after the following applicable embargo period has expired. See the 
following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.  
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D. CONTRIBUTIONS OWNED BY EMPLOYER  
If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a 
“work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution 
which must execute this Agreement (in addition to the Contributor’s signature). In such case, the 
company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to 
the Contribution for the full term of copyright throughout the world as specified in Section A above.  
 E. GOVERNMENT CONTRACTS  
In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may 
reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official 
U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, 
U.K. Government, and other government employees: see notes at end.) 
F. CONTRIBUTOR’S REPRESENTATIONS  
The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified 
as Contributors actually contributed to the Contribution, and all individuals who contributed are included. 
The Contribution is submitted only to this Journal and has not been published before. (If excerpts from 
copyrighted works owned by third parties are included, the Contributor will obtain written permission from 
the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit 
to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous 
or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent 
or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or 
injury.  Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing 
the data on which the Contribution is based for examination by the editors or their assignees. 
G. FINANCIAL DISCLOSURES 
The Contributor certifies that his/her financial and material support for this research and work, regardless of 
date, is clearly identified on Exhibit A to this Agreement.  The Contributor has also identified on Exhibit A, 
all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, 
advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, 
or stock ownership in medically-related fields). 
H. VIDEO AND PHOTOGRAPHY CONSENT 
In the event that the Contribution includes, discloses or incorporates any content (including, without 
limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable 
content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or 
incorporation and that this consent fully complies with all legal requirements, including without limitation, 
all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician 
are subject, including the United States Health Insurance Portability and Accountability Act of 1996 
(“HIPAA”) if applicable.  The Contributor hereby certifies that, if the patient consent form is in a language 
other than English, such consent form meets all of the requirements set forth in the Instructions to Authors.  
In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the 
patient identifiable content in both print and online (i.e., internet/web-based) publication formats.  The 
Contributor further certifies that the person executing any such patient consent form, to the best of his/her 
knowledge, had legal capacity under applicable law to execute the form on behalf of the patient. 
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I. ACKNOWLEDGEMENTS 
The Contributor should obtain written permission from all individuals named in the acknowledgement since 
readers may infer their endorsement of data and conclusions.  The Contributor certifies that all individuals 
named in the acknowledgement section have provided written permission to be named. 
J. MISCELLANEOUS 
This Agreement may be amended or modified only in a writing executed by both parties.  The waiver or 
failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other 
limitation of any other right or any future right.  This Agreement shall inure to the benefit of, and shall be 
binding upon, the parties, their respective successors and permitted assigns.  This Agreement may be 
executed in two (2) or more counterparts, each of which shall be an original and all of which taken together 
shall constitute one and the same agreement.  Executed copies of this Agreement may be delivered by 
facsimile transmission, pdf/email or other comparable electronic means.  If for any reason any provision of this 
Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the 
validity, legality and enforceability of the remainder of this Agreement shall not be affected and such 
provision shall be deemed modified to the minimum extent necessary to make such provision consistent with 
applicable law and, in its modified form, such provision shall then be enforceable and enforced.  The parties 
agree to do such further acts and to execute and deliver such additional agreements and instruments from 
time to time as either may at any time reasonably request in order to assure and confirm unto such requesting 
party the rights, powers and remedies conferred in the Agreement.  This Agreement, including any exhibits 
attached hereto, contains the entire agreement and understanding of the parties with respect to the subject 
matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and 
oral, relating thereto.
All Contributors must sign below.  Contributors must check one box except that NIH grantees should 
check both Contributor-owned work and the NIH grantee box.  If your Contribution was written 
during the course of employment, your employer must also sign where indicated. 
Please send your original completed and signed forms by fax or email a scanned copy to the Journal 
production editor.  For production editor contact details please visit the Journal’s online author guidelines.  
Do not send in hard copies of these forms. 
[ ] Contributor-owned work        
     Contributor’s signature    Date 
            
     Type or print name and title 
            
     Co-Contributor’s signature   Date 
            
     Type or print name and title 
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[ ] Company/Institution-owned         
   Work (made-for-hire in the  Company or Institution (Employer-for-Hire) Date 
   Course of employment) 
 
             
     Authorized signature of Employer  Date 
 
 
              
     Contributor’s signature    Date 
 
      
           
     Type or print name and title 
 
 
ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY 
 
 
 
 
 [ ] U.S. Government work  
Note to U.S. Government Employees 
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or 
which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public 
domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type 
his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution 
will be published in the United States and other countries. If the Contribution was not prepared as part of 
the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work. 
 
[ ] U.K. Government work (Crown Copyright)  
Note to U.K. Government Employees 
The rights in a contribution prepared by an employee of a UK government department, agency or other 
Crown body as part of his/her official duties, or which is an official government publication, belong to the 
Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate 
authorisation to publish. If your status as a government employee legally prevents you from signing this 
Agreement, please contact the Journal production editor. 
 
[ ] Other  
Including Other Government work or Non-Governmental Organisation work 
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees 
If your status as a government or non-governmental organisation employee legally prevents you from 
signing this Agreement, please contact the Journal production editor. 
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 Exhibit A 
 
Financial Disclosure 
 
The Contributor has received financial and material support for this research and work regardless of date 
from the following sources: 
Name:        
Address:       
Type of support:       
This material will be printed with the published article. 
 
 
In the past year from the date of submission, the Contributor has also received the following support 
unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, 
royalties, expert testimony, partnerships, or stock ownership in medically-related fields): 
 
Name:        
Address:       
Type of support:       
This material will be posted on the journal website and may be printed at the Editors’ discretion. 
 
 
ATTACH ADDITIONAL INFORMATION AS NECESSARY 
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COPYRIGHT TRANSFER AGREEMENT 
Date:      
Contributor name:          
Contributor address:          
Manuscript number:          
Re: Manuscript entitled:           (the “Contribution”)  
for publication in:  Movement Disorders Clinical Practice (the “Journal”)  
Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the 
“Owner”) 
Dear Contributor(s):  
Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing 
process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this 
Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the 
Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed 
without a signed copy of this Agreement. 
 
A. COPYRIGHT  
The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all 
copyright in and to the Contribution, and all rights therein, including but not limited to the right to 
reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole 
or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all 
languages and in all media of expression now known or later developed, and to license or permit others to do 
so.  
B. RETAINED RIGHTS  
Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all 
proprietary rights other than copyright, such as patent rights, in any process, procedure or article of 
manufacture described in the Contribution.   This reservation of rights does not affect or limit the rights 
assigned to Owner in Section A.  
C. PERMITTED USES BY CONTRIBUTOR  
1. License.  The Owner grants to Contributor a non-exclusive, non-transferable and limited license to 
reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the 
original form submitted to the Journal prior to the peer review process, solely to colleagues within the 
Contributor’s nonprofit organization or educational institution.  The Contributor shall make no more than 
100 printed copies of the preprints in any calendar year.   Such preprints may be posted as electronic files on 
the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit 
organization or educational institution, or on a secure external website at the Contributor’s nonprofit 
organization or educational institution, provided that access is limited to employees and/or students at 
Contributor’s non-profit organization or educational institution.    Contributor shall not charge a fee for any 
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preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any 
systematic external distribution (e.g., posting on a listserve, public website, database connected to a public 
access server, or automated delivery system).  The license grant in this Section does not apply to for-profit 
corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing 
by the Owner.  The rights granted to Contributor under this Section C do not include reproduction, 
distribution or any other use of rating scales, videos or other audiovisual materials associated with the 
Contribution. 
2. Required Citation.  Prior to publication, the Contributor must provide full credit and acknowledgement 
of the Journal in all preprints in the following format:  This is a preprint of an article accepted for 
publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder 
Society.   After publication, the Contributor must provide a citation to the Journal in all preprints in the 
following format:  This is a preprint of an article that was published in [Journal title]:  (Title of Article, 
Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and 
Movement Disorder Society).  An electronic link must be provided to the Journal’s website, located at 
http://www.interscience.Wiley.com.  The Contributor agrees not to update the preprint or replace it with the 
published version of the Contribution.    
3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version 
of the Contribution (the “Accepted Version”) is not permitted under this Agreement.  There are separate 
arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms 
apply if the Contributor receives or received funding from these agencies. The details of those relationships, 
and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/ 
funderstatement.  
4. Additional Terms for Certain Funders.  Certain funders, including the NIH, members of the Research 
Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository 
after an embargo period.   Details of funding arrangements are set out at the following website: 
http://www.wiley.com/go/funderstatement.  Additional terms may be applicable.  Please contact the 
production editor for the journal at MDCPprod@wiley.com if you have additional funding requirements. 
If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, 
the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository 
after the following applicable embargo period has expired, subject to further conditions imposed by the 
RCUK:  
a. 12 months from first publication online of the final published version of the Contribution for 
research funded by members of the Research Councils UK (RCUK) other than The 
Economic and Social Research Council (ESRC) and the Arts and Humanities Research 
Council (AHRC); or 
b. 24 months from first publication online of the final published version of the Contribution for 
research funded by ESRC or AHRC. 
5.  Additional Terms for Certain Institutions.  Wiley has arrangements with certain educational 
institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo 
period.    Details of such arrangements are set out at the following website: 
http://olabout.wiley.com/WileyCDA/Section/id-406074.html . Additional terms may be applicable. 
If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s 
OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in 
the educational institution’s repository after the following applicable embargo period has expired. See the 
following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.  
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D. CONTRIBUTIONS OWNED BY EMPLOYER  
If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a 
“work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution 
which must execute this Agreement (in addition to the Contributor’s signature). In such case, the 
company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to 
the Contribution for the full term of copyright throughout the world as specified in Section A above.  
 E. GOVERNMENT CONTRACTS  
In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may 
reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official 
U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, 
U.K. Government, and other government employees: see notes at end.) 
F. CONTRIBUTOR’S REPRESENTATIONS  
The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified 
as Contributors actually contributed to the Contribution, and all individuals who contributed are included. 
The Contribution is submitted only to this Journal and has not been published before. (If excerpts from 
copyrighted works owned by third parties are included, the Contributor will obtain written permission from 
the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit 
to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous 
or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent 
or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or 
injury.  Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing 
the data on which the Contribution is based for examination by the editors or their assignees. 
G. FINANCIAL DISCLOSURES 
The Contributor certifies that his/her financial and material support for this research and work, regardless of 
date, is clearly identified on Exhibit A to this Agreement.  The Contributor has also identified on Exhibit A, 
all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, 
advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, 
or stock ownership in medically-related fields). 
H. VIDEO AND PHOTOGRAPHY CONSENT 
In the event that the Contribution includes, discloses or incorporates any content (including, without 
limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable 
content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or 
incorporation and that this consent fully complies with all legal requirements, including without limitation, 
all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician 
are subject, including the United States Health Insurance Portability and Accountability Act of 1996 
(“HIPAA”) if applicable.  The Contributor hereby certifies that, if the patient consent form is in a language 
other than English, such consent form meets all of the requirements set forth in the Instructions to Authors.  
In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the 
patient identifiable content in both print and online (i.e., internet/web-based) publication formats.  The 
Contributor further certifies that the person executing any such patient consent form, to the best of his/her 
knowledge, had legal capacity under applicable law to execute the form on behalf of the patient. 
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[ ] Company/Institution-owned         
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